Skip to main content

Market Overview

Inovio Coronavirus Vaccine Study Shows Months Of Immunity In Primates, Sending Stock Higher

Inovio Coronavirus Vaccine Study Shows Months Of Immunity In Primates, Sending Stock Higher

Inovio Pharmaceuticals Inc (NASDAQ: INO) shares were moving to the upside Thursday after slipping 6.3% in the prior session. 

What Happened: Plymouth, Pennsylvania-based Inovio, which is developing a DNA vaccine codenamed INO-4800 against the novel coronavirus, said the investigational vaccine was found effective in protecting rhesus macaques from a live virus challenge 13 weeks after the last vaccination.

Macaques receiving two 1mg doses of INO-4800  four weeks apart were challenged with live virus 13 weeks after the second dose — week 17 of the study.

INO-4800 was found to be effective in reducing viral load in both the lower lungs and nasal passages, the company said.

The protection was achieved due to memory T and B cell immune responses from INO-4800, according to Inovio.

Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.

Why It's Important: Inovio said INO-treated animals demonstrated seroconversion after a single dose of vaccine, with protective neutralizing antibodies and T cells lasting in the blood for more than four months after the initial dose.

More importantly, the antibody levels and T cell responses were significantly higher than found in convalescent patients, the company said. 

Unlike previously reported monkey vaccine challenge studies that were conducted at the time of peak immune responses — one to four weeks from the last vaccination — INO-4800 offered memory immune response, Inovio said.

"We are very encouraged with the duration of protection that INO-4800 demonstrated in this NHP study and look forward to reassessing its impact on durability of response at 12 months out from our other ongoing non-human primate and animal challenge studies," Kate Broderick, Inovio's senior vice president of R&D, said in a statement. 

INO-4800 is being evaluated in a Phase 1 study in the U.S., and preliminary results from the study released in late June showed an overall immunological response rate of 94%. The company said it expects to commence a Phase 2/3 trial in summer.

INO Price Action: Inovio shares were trading 9.45% higher at $21.32 at last check Thursday. 

Related Links:

The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings

Inovio Analyst Downgrades COVID-19 Vaccine Developer, Says Risk Higher After Rally


Related Articles (INO)

View Comments and Join the Discussion!

Posted-In: Coronavirus Covid-19Biotech News Health Care Movers Trading Ideas General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at